Comparison of the Anticoagulant Response of a Novel Fluorogenic Anti-FXa Assay wth Two Commercial Anti-FXa Chromogenic Assays by Harris, Leanne F et al.
Technological University Dublin 
ARROW@TU Dublin 
Articles School of Biological Sciences 
2011 
Comparison of the Anticoagulant Response of a Novel 
Fluorogenic Anti-FXa Assay wth Two Commercial Anti-FXa 
Chromogenic Assays 
Leanne F. Harris 
Technological University Dublin, leanne.harris@tudublin.ie 
Aoife O'Brien 
Dublin City University 
Vanessa Castro-Lopez 
CIC microGUNE 
James S. O'Donnell 
Trinity College Dublin, Ireland 
Anthony J. Killard 
University of the West of England, Bristol 
Follow this and additional works at: https://arrow.tudublin.ie/scschbioart 
 Part of the Biology Commons 
Recommended Citation 
Harris, L. et al. (2011) Comparison of the anticoagulant response of a novel fluorogenic anti-FXa assay 
with two commercial anti-FXa chromogenic assays. Thrombosis Research, 128 (6). pp. 166-170, 2011. 
doi:10.1016/j.thromres.2011.08.002 
This Article is brought to you for free and open access by 
the School of Biological Sciences at ARROW@TU Dublin. 
It has been accepted for inclusion in Articles by an 
authorized administrator of ARROW@TU Dublin. For more 
information, please contact 
yvonne.desmond@tudublin.ie, arrow.admin@tudublin.ie, 
brian.widdis@tudublin.ie. 
This work is licensed under a Creative Commons 
Attribution-Noncommercial-Share Alike 3.0 License 
                             Elsevier Editorial System(tm) for Thrombosis Research 
                                  Manuscript Draft 
 
 
Manuscript Number:  
 
Title: Comparison of the anticoagulant response of a novel fluorogenic anti-FXa assay with two 
commercial anti-FXa chromogenic assays  
 
Article Type: Regular Article 
 
Corresponding Author: Prof Anthony J Killard, PhD 
 
Corresponding Author's Institution: University of the West of England 
 
First Author: Leanne  F Harris, PhD 
 
Order of Authors: Leanne  F Harris, PhD; Anthony J Killard, PhD; Aoife O'Brien, MSc; Vanessa Castro-
López, PhD; James S O'Donnell, M.D., PhD 
 
Abstract: Introduction: Fast and accurate monitoring is crucial in the successful regulation of 
coagulation therapy. For the treatment of venous thromboembolism, both unfractionated heparin 
(UFH) and low molecular weight heparins (LMWH) are commonly administered. The chromogenic 
anti-factor Xa (FXa) assay is currently considered the 'gold standard' assay for monitoring LMWH. 
However different commercial chromogenic methods often differ when tested with the same samples. 
Fluorogenic anti-FXa assays have the potential to offer greater benefits over chromogenic assays in 
terms of greater specificity, sensitivity and they are not so influenced by sample opacity or turbidity. 
Materials and Methods: Commercial plasmas were spiked with pharmacologically relevant 
concentrations (0-1 U/ml) of UFH, enoxaparin, and tinzaparin. The fluorogenic assay was carried out 
using previously optimized concentrations of 4 nM FXa and 0.9 µM fluorogenic substrate, in addition to 
6.25 µl of 100 mM CaCl2 and 43.75 µl of plasma. The Biophen® and Coamatic chromogenic assays 
were carried out according to the manufacturer's instructions. Reaction rates and endpoint values 
were analyzed and statistical analysis by means of one-way analysis of variance (ANOVA) was 
performed. 
Results: The fluorogenic anti-FXa assay was found to have the broadest therapeutic range of 0-1 U/ml 
with CVs of < 5% for UFH and tinzaparin and CVs < 9% for enoxaparin. Despite their limited measuring 
range, excellent reproducibility was observed with both chromogenic assays 
Conclusions: This study indicated that the fluorogenic assay is the most sensitive assay with the 
broadest dynamic range for monitoring LMWH therapy when compared with standard chromogenic 
assays. 
 
 
 
 
 1 
Comparison of the anticoagulant response of a novel fluorogenic anti-FXa assay 
with two commercial anti-FXa chromogenic assays 
 
 
 
Leanne F. Harris
a, Aoife O’Briena, Vanessa Castro-Lópeza James S. O’Donnella,b, 
Anthony J. Killard
c 
 
 
a
Biomedical Diagnostics Institute, National Centre for Sensor Research, Dublin City 
University, Dublin 9, Ireland. 
b
Haemostasis Research Group, Trinity College Dublin, and National Centre for 
Hereditary Coagulation Disorders, St. James’s Hospital, Dublin 8, Ireland. 
c
Department of Applied Sciences, University of the West of England, Coldharbour 
Lane, Bristol BS16 1QY, UK. 
 
c
Corresponding Author: Prof. Anthony J. Killard.  
Department of Applied Sciences, University of the West of England, Coldharbour 
Lane, Bristol BS16 1QY, UK. 
Tel: + 00 44 1173282967 
Fax: + 00 44 1173282904 
E-mail: tony.killard@uwe.ac.uk 
 
Word count: 3,130 words (excluding abstract and references). 
Harrisetal.manuscript
 2 
Abstract 
Introduction: Fast and accurate monitoring is crucial in the successful regulation of 
coagulation therapy. For the treatment of venous thromboembolism, both 
unfractionated heparin (UFH) and low molecular weight heparins (LMWH) are 
commonly administered. The chromogenic anti-factor Xa (FXa) assay is currently 
considered the ‘gold standard’ assay for monitoring LMWH. However different 
commercial chromogenic methods often differ when tested with the same samples. 
Fluorogenic anti-FXa assays have the potential to offer greater benefits over 
chromogenic assays in terms of greater specificity, sensitivity and they are not so 
influenced by sample opacity or turbidity. 
Materials and Methods: Commercial plasmas were spiked with pharmacologically 
relevant concentrations (0–1 U/ml) of UFH, enoxaparin, and tinzaparin. The 
fluorogenic assay was carried out using previously optimized concentrations of 4 nM 
FXa and 0.9 µM fluorogenic substrate, in addition to 6.25 µl of 100 mM CaCl2 and 
43.75 µl of plasma. The Biophen® and Coamatic chromogenic assays were carried 
out according to the manufacturer’s instructions. Reaction rates and endpoint values 
were analyzed and statistical analysis by means of one-way analysis of variance 
(ANOVA) was performed. 
Results: The fluorogenic anti-FXa assay was found to have the broadest therapeutic 
range of 0-1 U/ml with CVs of < 5% for UFH and tinzaparin and CVs < 9% for 
enoxaparin. Despite their limited measuring range, excellent reproducibility was 
observed with both chromogenic assays 
Conclusions: This study indicated that the fluorogenic assay is the most sensitive 
assay with the broadest dynamic range for monitoring LMWH therapy when 
compared with standard chromogenic assays.  
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Introduction 
Anticoagulants including unfractionated heparin (UFH) and low molecular weight 
heparins (LMWHs) are commonly administered to patients for the treatment of 
cardiovascular diseases such as arterial thromboembolism and coronary artery disease 
[1-3]. While UFH can be monitored using conventional clot-based says such as the 
activated partial thromboplastin time (APTT) and activated clotting time (ACT), these 
tests cannot be used to accurately determine LMWH activity [3-6]. However, the 
development of anti-factor Xa (FXa) assays and their use in central diagnostic 
laboratories has allowed for more accurate and sensitive monitoring of LMWH 
therapy [5, 7, 8].  
The standard anti-FXa assays currently used for clinical monitoring of LMWH are 
chromogenic-based assays [9, 10]. The introduction of synthetic substrates for the 
testing of serine proteases and their inhibitors began in the 1950s [11]. In 1972 
oligopeptide p-nitroanilides were developed, which were proven to be sensitive to 
thrombin, plasmin, and trypsin [12]. These oligopeptide substrates were coupled to 
the chromophore p-nitroaniline (pNA) via an amide linkage so that the protease to be 
assayed could hydrolyze the chromogenic tripeptide-pNA, releasing the yellow pNA 
which could be detected photometrically at 405 nm [11]. Research into synthetic 
substrates continued with an increased focus on the measurement of antithrombin 
(AT) and FXa. The first anti-FXa chromogenic assay was developed by Teien in 
1976. It utilised FXa and the chromogenic substrate Bz-Ile-Glu-Gly-Arg-pNA in a 
simple two-stage assay. Stage one involved FXa incubation with test plasma followed 
by stage two which focused on the determination of remaining FXa activity through 
amidolysis of the substrate. The accuracy and precision of this newly developed assay 
compared favourably with that of existing clotting assays in use, resulting in the 
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adaptation of this assay by central haemostasis laboratories as the standard for 
LMWH monitoring [13-15]. 
Although chromogenic assays confer many advantages over standard clot-based 
assays, such as their increased sensitivity to LMWHs, they do have several limitations 
including poor comparability between commercially available anti-FXa
 
chromogenic 
assays,
 
differences in ratios of anti-FXa to anti-FIIa
 
among the various LMWH 
preparations, and the variability caused by the timing of blood sampling in relation to 
dosing [16, 17]. As the testing method relies on optical density readings, it requires 
samples to be relatively clear which precludes the use of whole blood and platelet rich 
plasma (PRP) samples from chromogenic assay testing, as the sample density 
interferes with colorimetric measurements [18]. This problem is also encountered in 
the presence of fibrinogen clotting, as the increased turbidity of the sample interferes 
negatively with the absorbance readings [13, 18, 19].  
With fluorogenic assays on the other hand, it is possible to test a range of sample 
types such as platelet poor plasma (PPP), PRP, and whole blood samples, as 
fluorescence is not influenced by sample opacity [19, 20]. Fluorogenic assays became 
increasingly popular for proteolytic assays in the 1970s [21] and several fluorogenic 
substrates for both thrombin and FXa were introduced [22, 23] aiding in the 
development of fluorogenic assays for coagulation testing. 
In this study we assessed if the novel fluorogenic anti-FXa assay previously 
developed in our laboratory [20] would compare favourably with two commercially 
available anti-FXa chromogenic assays, when tested with pooled human plasma 
containing therapeutic concentrations of UFH and two LMWHs. 
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Materials and methods 
Reagents 
Water (ACS reagent) and HEPES (minimum 99.5% titration) were purchased from 
Sigma-Aldrich (Dublin, Ireland). Filtered HEPES was prepared at a concentration of 
10 mM (pH 7.4). A 100 mM filtered stock solution of CaCl2 from Fluka BioChemika 
(Buchs, Switzerland) was prepared from a 1 M CaCl2 solution.  
The fluorogenic substrate methylsulfonyl-D-cyclohexylalanyl-glycyl-arginine-7-
amino-4-methylcoumarin acetate (Pefafluor FXa) was purchased from Pentapharm 
(Basel, Switzerland). It was reconstituted in 1 ml of water having a stock 
concentration of 10 mM, aliquoted and stored at -20 °C. Dilutions from 10 mM stock 
solutions down to 10 µM were freshly prepared with water when needed. Subsequent 
dilutions were prepared in 10 mM HEPES. Tubes were covered with aluminum foil to 
protect from exposure to light. Purified human FXa (serine endopeptidase; code 
number: EC 3.4.21.6) was obtained from HYPHEN BioMed (Neuville-Sur-Oise, 
France) and was reconstituted in 1 ml of PCR grade water to give a stock 
concentration of 2200 nM.  
The Biophen® Heparin Anti-Xa chromogenic kit was purchased from Hyphen 
BioMed (Neuville-Sur-Oise, France) and the Coamatic® Heparin chromogenic kit 
was obtained from Chromogenix (Milano, Italy). Unfractionated heparin (sodium salt 
of heparin derived from bovine intestinal mucosa, H0777) was sourced from Sigma-
Aldrich (Dublin, Ireland), Tinzaparin (Innohep®) and Enoxaparin (Clexane®) were 
obtained from LEO Pharma (Ballerup, Denmark) and Sanofi-Aventis (Paris, France) 
respectively. Human pooled plasma was purchased from Helena Biosciences Europe 
(Tyne and Wear, UK). Lyophilized plasma was reconstituted in 1 ml of water and left 
to stabilize for at least 20 min at room temperature prior to use. 
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Apparatus and software 
Absorbance and fluorescence measurements were performed in a Spectrophotometer 
Infinite M200 microplate reader from Tecan Group Ltd, (Männedorf, Switzerland) 
equipped with a UV Xenon flashlamp. Flat, black-bottom 96-well polystyrol 
FluorNunc™ microplates from Thermo Fisher Scientific (Roskilde, Denmark) were 
used for fluorescence measurements. Flat, transparent 96-well Greiner® microplates 
from Greiner Bio-One (Gloucestershire, United Kingdom) were used for absorbance 
measurements. 
Fluorogenic anti-FXa assay 
All measurements for the fluorogenic anti-FXa assay were carried out in reconstituted 
citrated human pooled plasma without the addition of exogenous AT. Pooled 
commercial plasma samples were spiked with pharmacologically relevant 
concentrations (0–1 U/ml) of therapeutic anticoagulants including UFH, enoxaparin, 
and tinzaparin. FXa and Pefafluor FXa fluorogenic substrate concentrations were 
previously optimized as 4 nM and 0.9 µM respectively for the fluorogenic anti-FXa 
assay [20]. Each well contained 6.25 µl of 100 mM CaCl2, 43.75 µl of pooled plasma, 
and 50 µl of FXa. The reaction was started by adding 50 µl of Pefafluor FXa 
fluorogenic substrate. Samples within wells were mixed with the aid of orbital 
shaking at 37 °C for 30 s. Immediately after shaking, fluorescence measurements 
were recorded at 37 °C for 60 min, with a 20 µs integration time.  Fluorescence 
excitation was at 342 nm and emission was monitored at 440 nm, corresponding to 
the excitation/emission wavelengths of the 7-amino-4-methylcoumarin (AMC) 
fluorophore. All the measurements were carried out in triplicate.  
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Commercial chromogenic assays 
All measurements for the chromogenic anti-FXa assays were carried out in 
reconstituted citrated human pooled plasma. Pooled commercial plasma samples were 
spiked with pharmacologically relevant concentrations (0–1 U/ml) of therapeutic 
anticoagulants including UFH, enoxaparin, and tinzaparin. The Biophen® Heparin 
chromogenic assay was carried out according to the manufacturer’s instructions as 
follows: each well contained 50 µl of plasma and 50 µl of antithrombin (AT). To this, 
50 µl of FXa was added. The reaction was started by adding 50 µl of FXa specific 
chromogenic substrate. Samples within wells were mixed within the 
spectrophotometer by orbital shaking at 37 ºC for 30 s. Immediately after shaking, 
absorbance measurements were recorded at 37 ºC for 60 min, at 10 s intervals. 
Absorbance was measured at 405 nm and all measurements were performed in 
triplicate. The exact same procedure was followed for the Coamatic® Heparin 
chromogenic assay without the addition of 50 µl of AT. 
Data and statistical analysis 
All graphs were plotted using SigmaPlot 8.0. Data generated from the fluorogenic and 
chromogenic anti-FXa assays were plotted as absorbance/fluorescence intensity 
versus time. The analytical parameter for the fluorogenic assay was defined as the 
reaction rate (slope), which can be described as the change in fluorescence divided by 
the change in time (i.e. dF/dt). This is the linear portion of the fluorescence response 
profile and is plotted against different anticoagulant concentrations to generate a dose-
response curve. Following analysis of the response profiles for both the commercial 
chromogenic assays, it was clear that the reaction rate was an unsuitable analytical 
parameter, and therefore the endpoint value was selected to construct dose-response 
curves for these assays.  
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SPSS 17.0 was used for statistical analysis and all data was transformed 
logarithmically prior to analysis. Intra-assay differences between anticoagulant 
concentrations were compared using one-way analysis of variance (ANOVA), with 
subsequent post-hoc analysis (Scheffe test, Tukey’s test, and Duncan’s test) if 
significance was observed. A result of p<0.05 was considered statistically significant. 
Assay comparisons were then performed based on the sensitivity and responsiveness 
of each assay as established by the intra-assay statistical analysis. 
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Results 
All three anticoagulants tested in the fluorogenic anti-FXa assay resulted in similar 
fluorescence profiles so a representative graph is shown in Fig. 1. As can be seen in 
Fig. 1, all profiles at each concentration reached maximum plateau between 20000 
and 25000 arbitrary units (AU), the lag time increased with increasing anticoagulant 
concentration and the slope of the curve decreased with increasing concentration. 
Analysis of the normalized dose-response curves in Fig. 2, which were generated 
from the initial reaction rates of the profiles, showed that the fluorogenic anti-FXa 
assay was sensitive to UFH, tinzaparin, and enoxaparin from 0 U/ml to 1 U/ml. 
Statistical analysis of the logarithmically transformed data using one-way ANOVA, 
proved that the assay was capable of differentiating all anticoagulant concentrations at 
intervals of 0.2 U/ml from 0 to 1 U/ml (p<0.05), indicating a high degree of assay 
sensitivity across the dynamic range. The assay was reproducible with CVs of < 5% 
for UFH and tinzaparin and < 9% CV for enoxaparin. 
The absorbance profiles generated by the chromogenic assays differed from the 
profiles generated by the fluorogenic assay. While the fluorescence profiles at each 
concentration began with a short lag time, rapid increase and plateau at the same 
level, the chromogenic profiles lacked a lag time, they demonstrated a decreasing 
reaction rate with increasing anticoagulant concentration and as concentration 
increased each progress curve reached a different level of absorbance intensity. An 
example of this can be seen in Fig. 3. 
Visual analysis of the absorbance profiles at increasing concentrations of UFH in the 
Biophen® chromogenic assay (Fig. 3) indicated a high degree of sensitivity to UFH 
over the dynamic range. In Fig. 4 the dose-response curve based on the extracted 
endpoint values can be seen. 
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Logarithmic transformation of the endpoint values returned statistically significant 
differences between concentrations from 0 to 1 U/ml for UFH (p<0.05). Analysis of 
the tinzaparin dose-response profile in Fig. 4 indicates high assay sensitivity at low 
concentrations of tinzaparin but at high concentrations the assay becomes less 
sensitive. Statistical analysis, using one-way ANOVA followed by post-hoc analysis, 
of the endpoint values returned significant differences (p<0.05) between 
concentrations up to 0.6 U/ml. Statistical analysis of the dose-response profile for 
enoxaparin in the Biophen® chromogenic assay (Fig. 4) indicated that the differences 
recorded between plasma samples up to 0.4 U/ml were significant (p<0.05). Assay 
reproducibility was very good with CVs of < 5% for all drugs tested. 
The absorbance profiles generated by plasma samples spiked with UFH from 0 to 1 
U/ml using the Coamatic® chromogenic assay are shown in Fig. 5. Using the 
endpoint values, a dose-response curve (Fig. 6) was generated. Logarithmic 
transformation of the endpoint values resulted in statistically significant differences 
(p<0.05) between 0 and 0.4 U/ml for UFH. Statistical analysis of the dose-response 
curve (Fig. 6) indicated sensitivity to tinzaparin and enoxaparin up to 0.6 U/ml and 
0.4 U/ml respectively. Assay reproducibility again was excellent with CVs of < 5% 
for all drugs tested. 
All assays showed excellent reproducibility with CVs < 9%, but the fluorogenic anti-
FXa assay returned the broadest dynamic range. A summary of the statistically 
sensitive ranges for all drugs tested with each assay and the reproducibility of each is 
outlined in Table 1. 
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Discussion 
Chromogenic anti-FXa assays are currently the ‘gold standard’ for monitoring UFH 
and LMWH therapy in patients suffering from thrombotic disorders [16, 24, 25]. 
Chromogenic assays were first introduced in the 1960s with the development of 
synthetic peptide substrates for various coagulation proteases such as thrombin and 
FXa [11-13]. Greater reproducibility was achieved with these assays than had 
previously been observed with traditional clot-based assays, hence their immediate 
uptake into central haemostasis laboratories [14]. It has been further suggested that 
the way forward is to monitor anti-FXa levels in rapid assay formats developed 
specifically for point-of-care testing [5]. 
In this study the aim was to compare a novel fluorogenic anti-FXa assay to currently 
available commercial anti-FXa chromogenic kits in a bid to ascertain if the 
fluorogenic anti-FXa assay could offer a similar or greater level of sensitivity to the 
anticoagulants under evaluation. The fluorogenic anti-FXa assay was compared with 
two commercially available chromogenic assay kits; the Biophen® and the 
Coamatic® chromogenic kits. All assays were performed using human pooled plasma 
samples spiked with therapeutic concentrations of UFH and two LMWHs, 
enoxaparin, and tinzaparin. The intra-assay variability and dynamic ranges for these 
three drugs was established for each assay. Different analytical parameters were 
selected to determine the intra-assay variability for the chromogenic and fluorogenic 
assays. The responses of the fluorogenic and chromogenic assays to the three different 
drugs were then compared in terms of dynamic range. 
From the results obtained in this study, it was established that the FXa fluorogenic 
assay had the broadest dynamic range for each drug. UFH was detected up to a 
concentration of 1 U/ml in both the fluorogenic anti-FXa assay and the Biophen® 
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chromogenic assay, with much lower levels of sensitivity up to 0.4 U/ml with the 
Coamatic® kit. Tinzaparin was detected up to a concentration of 1 U/ml in the 
fluorogenic assay and to a concentration of 0.6 U/ml in both commercially available 
chromogenic assay kits. The smallest dynamic range for all assays, with the exception 
of the fluorogenic anti-FXa assay, was for enoxaparin. While the drug could be 
detected using the fluorogenic assay to 1 U/ml, both commercially available 
chromogenic assay kits could only detect up to levels of 0.4 U/ml. According to the 
manufacturer’s datasheets, both the Coamatic® and Biophen® kits are purported to 
be sensitive to anticoagulant (UFH and LMWH) concentrations of 1.5 U/ml and 1 
U/ml respectively with CVs of <6%. However, when performed as part of this study, 
while these assays were quite reproducible with CVs of <5%, they failed to reach 
their suggested therapeutic ranges, rendering the fluorogenic assay superior to the 
chromogenic assay in terms of its response to the anticoagulants tested. 
While significant variability in sensitivity between different coagulation methods 
(clot-based, chromogenic, and point-of-care) have been reported [3, 26, 27] 
significant differences often arise even when the method of testing is identical but the 
manufacturer of the test kit differs. 
For example, many studies have compared the responses of different anti-FXa 
chromogenic-based assays [16, 17, 28, 29]. In one such study, anti-FXa levels were 
compared using three different commercial chromogenic kits [17]. Results showed 
that even when performed according to the specifications of the manufacturer, 
different chromogenic methods returned significantly different anti-FXa levels for the 
same patient sample [17]. Kitchen et al. also investigated and compared five different 
chromogenic assays and observed a difference of > 0.25 U/ml in mean UFH levels 
between assays [29].  
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In the measurement of anti-FXa levels, variability in results for different chromogenic 
assays is common. In a comment to the editor of Chest in 2002, Smythe et al. [30] 
reported a mean difference of as high as 0.16 U/ml in heparin levels as deduced by 
anti-FXa analysis. Such differences are attributable to instrument and assay 
variability. It has thus been suggested that the therapeutic heparin range, as 
determined by anti-FXa assays, be instrument and assay specific [17, 30, 31]. Another 
study was also carried out comparing two chromogenic anti-FXa assays [16], the 
COATEST® and MODIFIED COAMATIC® assay from Chromogenix, and 
significant differences were observed between both methods in the high-dose UFH 
setting. The results again indicated that the choice of method used in a clinical setting 
requires careful consideration. It has been suggested that differences in the 
measurement of anti-FXa levels may be due to varying sensitivities of each specific 
method to the AT present endogenously in the sample. Therefore the addition of 
excess AT may aid in sample reproducibility [17]. 
Turbidity is a contributing factor to this variability in coagulation testing, especially in 
relation to chromogenic testing. Lyophilization of commercial plasmas induces 
turbidity due to the presence of lipid containing complexes, chylomicrons and very 
low density lipoproteins [32]. Fluorogenic assays however, are not influenced by 
sample opacity and therefore a range of sample types such as PRP and whole blood 
with minimal sample preparation required can be used with this assay [7, 20]. 
Marked differences in the response of the two chromogenic assays to UFH and 
LMWH were observed in the study presented here, which can be corroborated by 
previous studies [17, 29]. The fluorogenic anti-FXa assay displayed a greater dynamic 
and sensitive range compared to the commercial chromogenic assays when tested 
with pooled plasma samples containing different anticoagulants. 
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To summarise, it has been established that the fluorogenic anti-FXa assay exhibits a 
broad dynamic range with both UFH and LMWHs. This sensitive range coupled with 
the potential of the assay to test more complex sample types than clot-based or 
chromogenic assays [7, 20], indicates that with further development, fluorogenic anti-
FXa assays could become a successful method for anticoagulant monitoring. 
                                              
 16 
Acknowledgements 
This work was supported by Enterprise Ireland under Grant No. TD/2009/0124. We 
would also like to thank Dr. Michael Parkinson in Dublin City University for his help 
with the statistical analysis in this study. 
 17 
References  
[1] Lim W. Using low molecular weight heparin in special patient populations. J 
Thromb Thrombolysis 2010;29:233-40.  
[2] Melnikova I. The anticoagulants market. 2009;8:353-4.  
[3] Saw J, Kereiakes DJ, Mahaffey KW, Applegate RJ, Braden GA, Brent BN, et al. 
Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-
Xa levels. Thromb Res 2003;112:301-6.  
[4] Hirsh J, Raschke R. Heparin and low-molecular-weight heparin - The Seventh 
ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 
2004;126:188S-203S.  
[5] Linkins LA, Julian JA, Rischke J, Hirsh J, Weitz JI. In vitro comparison of the 
effect of heparin, enoxaparin and fondaparinux on tests of coagulation. Thromb Res 
2002;107:241-4.  
[6] Abbate R, Gori AM, Farsi A, Attanasio M, Pepe G. Monitoring of low-molecular-
weight heparins in cardiovascular disease. Am J Cardiol 1998;82:33L-6L.  
[7] Castro-López V, Harris LF, O'Donnell JS, Killard AJ. Comparative study of 
Factor Xa fluorogenic substrates and their influence on the quantification of LMWHs. 
Anal Bioanal Chem 2011;399:691-700.  
[8] Baglin T, Barrowcliffe TW, Cohen A, Greaves M. Guidelines on the use and 
monitoring of heparin. Br J Haematol 2006;133:19-34.  
 18 
[9] Harenberg J. Is laboratory monitoring of low-molecular-weight heparin therapy 
necessary? Yes. J Thromb Haemost 2004;2:547-50.  
[10] Lehman CM, Frank EL. Laboratory Monitoring of Heparin Therapy: Partial 
Thromboplastin Time or Anti-Xa Assay? Lab Med 2009;40:47-51.  
[11] Fareed J, Messmore HL, Bermes EW. New Perspectives in Coagulation-Testing. 
Clin Chem 1980;26:1380-91.  
[12] Messmore HLJ, Fareed J, Kniffin J, Squillaci G, Walenga J. Synthetic Substrate 
Assays of the Coagulation Enzymes and their Inhibitors Comparison with Clotting 
and Immunologic Methods for Clinical and Experimental Usage. Ann N Y Acad Sci 
1981;370:785-97.  
[13] Teien AN, Lie M, Abildgaard U. Assay of Heparin in Plasma using a 
Chromogenic Substrate for Activated Factor-10. Thromb Res 1976;8:413-6.  
[14] Kitchen S. Problems in laboratory monitoring of heparin dosage. Br J Haematol 
2000;111:397-406.  
[15] Stief TW. Innovative tests of plasmatic hemostasis. Lab Med 2008;39:225-30.  
[16] Ignjatovic V, Summerhayes R, Gan A, Than J, Chan A, Cochrane A, et al. 
Monitoring Unfractionated Heparin (UFH) therapy: Which Anti Factor Xa assay is 
appropriate? Thromb Res 2007;120:347-51.  
[17] Kovacs MJ, Keeney M, MacKinnon K, Boyle E. Three different chromogenic 
methods do not give equivalent anti-Xa levels for patients on therapeutic low 
 19 
molecular weight heparin (dalteparin) or unfractionated heparin. Clin Lab Haematol 
1999;21:55-60.  
[18] Hemker H, Beguin S, Al Dieri R, Wagenvoord R, Nijhuis S, Giesen P. measuring 
thrombin activity in whole blood. 2006;PCT/EP2006/004945.  
[19] Ramjee MK. The Use of Fluorogenic Substrates to Monitor Thrombin 
Generation for the Analysis of Plasma and Whole Blood Coagulation. Anal Biochem 
2000;277:11-8.  
[20] Harris LF, Castro-López V, Hammadi N, O’Donnell JS, Killard AJ. 
Development of a fluorescent anti-factor Xa assay to monitor unfractionated and low 
molecular weight heparins. Talanta 2010;81:1725-30.  
[21] Zimmerman M, Ashe B, Yurewicz EC, Patel G. Sensitive Assays for Trypsin, 
Elastase, and Chymotrypsin using New Fluoroenic Substrates. Anal Biochem 
1977;78:47-51.  
[22] Bishop RC, Hudson PM, Mitchell GA, Pochron SP. Use of fluorogenic 
substrates for the assay of antithrombin III and heparin. Ann N Y Acad Sci 
1981;370:720-30.  
[23] Morita T, Kato H, Iwanaga S, Takada K, Kimura T, Sakakibara S. New 
Fluorogenic Substrates for Alpha-Thrombin, Factor-Xa, Kallikreins, and Urokinase. J 
Biochem 1977;82:1495-8.  
[24] Bates SM, Weitz JI. Coagulation assays. Circulation 2005;112:e53-60.  
 20 
[25] Henry TD, Satran D, Knox LL, Iacarella CL, Laxson DD, Antman EM. Are 
activated clotting times helpful in the management of anticoagulation with 
subcutaneous low-molecular-weight heparin? Am Heart J 2001;142:590-3.  
[26] Flom-Halvorsen HI, Ovrum E, Abdelnoor M, Bjornsen S, Brosstad F. 
Assessment of heparin anticoagulation: Comparison of two commercially available 
methods. Ann Thorac Surg 1999;67:1012-6.  
[27] Silvain J, Beygui F, Ankri A, Bellemain-Appaix A, Pena A, Barthelemy O, et al. 
Enoxaparin Anticoagulation Monitoring in the Catheterization Laboratory Using a 
New Bedside Test. J Am Coll Cardiol 2010;55:617-25.  
[28] Campbell PJ, Tirvengadum MA, Pickering W, Cohen H, Ryan KE. HEPTEST: a 
suitable method for monitoring heparin during pregnancy. Clin Lab Haematol 
1999;21:193-9.  
[29] Kitchen S, Iampietro R, Woolley AM, Preston FE. Anti Xa monitoring during 
treatment with low molecular weight heparin or danaparoid: Inter-assay variability. 
Thromb Haemost 1999;82:1289-93.  
[30] Smythe MA, Mattson JC. The heparin anti-Xa therapeutic range - Are we there 
yet? Chest 2002;121:303-4.  
[31] Armando Tripodi,Antonius van den Besselaar. Laboratory Monitoring of 
Anticoagulation: Where Do We Stand? Semin Thromb Hemost 2009;35:34-41.  
[32] Hirst CF, Poller L. The cause of turbidity in lyophilised plasmas and its effects 
on coagulation tests. J Clin Pathol 1992;45:701-3.  
 21 
Tables 
Assay Anticoagulant drug Sensitive range (U/ml) % CV 
Fluorogenic UFH 
Tinzaparin 
Enoxaparin 
0-1  
0-1  
0-1 
< 5% 
< 5% 
< 9% 
Chromogenic 
Biophen®  
UFH 
Tinzaparin 
Enoxaparin 
0-1 
0-0.6 
0-0.4 
< 5% 
< 5% 
< 5% 
Chromogenic 
Coamatic® 
UFH 
Tinzaparin 
Enoxaparin 
0-0.4 
0-0.6 
0-0.4 
< 5% 
< 5% 
< 5% 
 22 
Table Legends 
Table 1. Comparison of the statistically sensitive range for each anticoagulant tested 
in the three anti-FXa assays evaluated and the variability associated with each. 
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Figure Legends 
Fig. 1: Fluorescence profiles of the fluorogenic anti-FXa assay in the presence of 
UFH (0-1 U/ml) (arrow indicates increasing UFH concentration). 
Fig. 2: Normalised dose-response curves of the fluorogenic anti-FXa assay in the 
presence of UFH (●), tinzaparin (▲) and enoxaparin (■).  
Fig. 3: Absorbance profiles of the Biophen® chromogenic anti-FXa assay in the 
presence of UFH (0-1 U/ml) (arrow indicates increasing UFH concentration). 
Fig. 4: Normalised dose-response curves of the Biophen® chromogenic anti-FXa 
assay in the presence of UFH (●), tinzaparin (▲) and enoxaparin (■).  
Fig. 5: Absorbance profiles of the Coamatic® chromogenic anti-FXa assay in the 
presence of UFH (0-1 U/ml) (arrow indicates increasing UFH concentration). 
Fig. 6: Normalised dose-response curves of the Coamatic® chromogenic anti-FXa 
assay in the presence of UFH (●), tinzaparin (▲) and enoxaparin (■).  
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Table 1. Comparison of the statistically sensitive range for each anticoagulant tested in the 
three anti-FXa assays evaluated and the variability associated with each. 
Assay Anticoagulant drug Sensitive range (U/ml) % CV 
Fluorogenic UFH 
Tinzaparin 
Enoxaparin 
0-1  
0-1  
0-1 
< 5% 
< 5% 
< 9% 
Chromogenic 
Biophen®  
UFH 
Tinzaparin 
Enoxaparin 
0-1 
0-0.6 
0-0.4 
< 5% 
< 5% 
< 5% 
Chromogenic 
Coamatic® 
UFH 
Tinzaparin 
Enoxaparin 
0-0.4 
0-0.6 
0-0.4 
< 5% 
< 5% 
< 5% 
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